Summary

Antidotes to Factor Xa inhibitors are under development and should enhance the safety of the new oral anticoagulant (NOAC) agents. Reversal of a NOAC is necessary in certain circumstances, such as a spontaneous or provoked hemorrhage (rate of 10% to 20% in Phase 3 trials), an emergency or invasive procedure that requires the rapid reversal of anticoagulation, or serious bleeding in a critical organ.